PROTHENA CORPORATION PLCOption Award Agreement • May 6th, 2020 • Prothena Corp PLC • Pharmaceutical preparations
Prothena Corporation plc, an Irish public limited company (the “Company”), hereby grants an Option to acquire its Shares to the individual named below. The terms and conditions of the Option are set forth in this cover sheet, in the attached Option Award Agreement and in the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (the “Plan”). All capitalized terms used but not defined in this cover sheet and the attached Option Award Agreement will have the meanings ascribed to such terms in the Plan.
ContractLicense Agreement • May 6th, 2020 • Prothena Corp PLC • Pharmaceutical preparations
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
UNDERSTANDING RELATED TO LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTLicense, Development, and Commercialization Agreement • May 6th, 2020 • Prothena Corp PLC • Pharmaceutical preparations
This UNDERSTANDING RELATED TO LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (the “Understanding”) is made effective March 1, 2020 (the “Understanding Effective Date”) and hereby reflects the Parties’ understanding related to the LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (collectively, with all amendments thereto, being referred to as the “Agreement”) dated December 11, 2013 by and between Neotope Biosciences Limited (as of January 5, 2015 Prothena Biosciences limited, “Prothena Ireland”) with respect to all rights and obligations under this Agreement outside of the United States, and Prothena Biosciences Inc. (“Prothena US”) with respect to all rights and obligations under this Agreement in the United States (Prothena US, together with Prothena Ireland, “Prothena”), on the one hand, and F. Hoffmann-La Roche Ltd (“Roche Basel”) with respect to all rights and obligations under this Agreement outside of the United States, and Hoffmann-La Roche Inc. (“Roche Nutley”) wit
